Studies in human malaria; the protective and therapeutic action of SN 5241 against St. Elizabeth strain vivax malaria.

01 May 1949
RUHE DS, COOPER WC

SN-5241 is a close analogue of NIH- 2041, which was the subject of two earlier papers in this series (Coopers and Coatney, 1947; Coatney et al, 1947). The latter drug exhibited insufficient antimalarial activity to compensate for its many undesirable side actions, but a further exploration of the group yielded several compounds deemed worthy of trials in man. Preliminary studies conducted by Alving (in Wiselogle, 1946) showed that SN-5241 was tolerated in dosages up to 2.0 g per day without evidence of the pilomotor simulation or bradycardia, which occurred with SN 1796. Its activity against blood-induced McCoy strain, Plasmodium vivax, was found to be on the basis of total oral oral dosage, about 0.6 that of quinine. As a result of these observations, SN-5241 was selected for trial in sporozoite-induced vivax malaria to determine whether it would act as a prophylactic or curative agent. This report summarizes such trials in 21 prisoner volunteers at the United States Penitentiary, Atlanta, GA.

Full text: https://academic.oup.com/aje/article-abstract/49/3/346/110436?redirected...